Watson Reports Data for Overactive Bladder, Enlarged Prostate Products

Watson Pharmaceuticals presented clinical data on two Phase III products at the American Urological Association’s annual meeting.

In the first double-blind, randomized, parallel-group trial, investigators assessed the cardiac safety of silodosin, an investigational treatment for enlarged prostates. Investigators concluded that silodosin, unlike other alpha blockers, did not demonstrate any meaningful negative effect on the heart, the company said.

The second trial studied an investigational product for overactive bladder called oxybutynin chloride topical gel (OTG). Researchers found that OTG produces serum levels similar to an approved oxybutynin transdermal patch (Oxytrol) but demonstrated improved skin tolerability that may lead to greater patient acceptability and use.